Randomized evidence · Different populations and designs
A short eating-window trial found weight loss; an isocaloric trial asks why
TREAD published July 2026; comparator study published April 2024
The TREAD trial, published in July 2026 and used here as older evidence, randomized 61 adults with obesity and no diabetes to a ten-hour time-restricted eating window or standard counseling for 12 weeks; 52 completed. Mean weight change was about minus 4.59 kilograms versus minus 1.68 kilograms, a between-group difference of roughly 2.91 kilograms. Fat mass also fell. Exploratory changes in adipose gene expression are mechanistic clues, not proof of longer life or better long-term function. The small sample, short duration and incomplete follow-up limit extrapolation to years of eating patterns or to people with diabetes, older adults and prolonged fasts. NIH grants supported the research; the PubMed conflict disclosure lists a relevant cofounder role, consulting and royalties for one investigator, while other authors reported no conflicts. Funding and interests matter to interpretation without invalidating the randomized comparison.
A separate 2024 12-week randomized isocaloric trial enrolled 41 adults with obesity plus prediabetes or diet-controlled diabetes. Its time-restricted and usual-pattern groups lost roughly 2.3 and 2.6 kilograms, a difference not statistically established, with no clear glucose advantage. We checked the accessible abstract rather than the full paper for this issue; its AHA support is reported there. The two trials differ in population and calorie control, so one does not simply refute the other. Together they raise the testable question whether the timing window helps mainly by changing how much people eat. Neither trial studied prolonged fasting, clinical longevity or an individualized treatment plan.
Evidence status · Older context explicitly dated
Carnivore, prolonged fasting and TRT: no new outcome justifies a shortcut
Checked October 10; cited FDA action February 2025
We found no new controlled patient-centered trial at this Saturday cutoff that would support a prolonged-fast protocol, a carnivore longevity claim or testosterone as general age reversal. A 2026 carnivore review described a very limited evidence base, weak controls and uncertain long-term effects. Testimonials may describe an individual experience, but cannot isolate diet from total calories, medications, exercise or selection of people who enjoyed the result. A prolonged fast can carry dehydration, electrolyte, hypoglycemia and refeeding hazards, especially with illness or medication. This paper provides no dosing, meal schedule or fast prescription.
The FDA’s February 2025 testosterone class-label action followed cardiovascular safety evidence and removed a boxed warning about adverse cardiovascular outcomes; it also required blood-pressure warning language and retained the limitation for age-related low testosterone. That dated regulatory decision is not an endorsement of TRT for everyone seeking more energy or longer life. The agency subsequently invited discussion of indications, as earlier editions noted; a request for evidence is not an approval. A sound verdict would need larger, longer randomized studies in the relevant population measuring daily function, cardiovascular outcomes, fertility and adverse effects. Anyone considering treatment needs a clinician’s assessment rather than a newspaper shortcut.